European Drug Report 2017

About this report

The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin and 30 Country Drug Reports, it makes up the 2017 European Drug Report package.

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the central source and confirmed authority on drug-related issues in Europe. For over 20 years, it has been collecting, analysing and disseminating scientifically sound information on drugs and drug addiction and their consequences, providing its audiences with an evidence-based picture of the drug phenomenon at European level.

The EMCDDA’s publications are a prime source of information for a wide range of audiences including: policymakers and their advisors; professionals and researchers working in the drugs field; and, more broadly, the media and general public. Based in Lisbon, the EMCDDA is one of the decentralised agencies of the European Union.

Download PDF Report

Cannabis
Adults
(15-64)
Used:
Last year23.5 million
 
Lifetime87.7 million
 
Young adults
(15-34)
Last year17.1 million
 
Estimates

National estimates of use in last year

Cocaine
Adults
(15-64)
Used:
Last year3.5 million
 
Lifetime17.5 million
 
Young adults
(15-34)
Last year2.3 million
 
Estimates

National estimates of use in last year

MDMA
Adults
(15-64)
Used:
Last year2.7 million
 
Lifetime14.0 million
 
Young adults
(15-34)
Last year2.3 million
 
Estimates

National estimates of use in last year

Amphetamines
Adults
(15-64)
Used:
Last year1.8 million
 
Lifetime12.5 million
 
Young adults
(15-34)
Last year1.3 million
 
Estimates

National estimates of use in last year

Opioids
High-risk opioid users1.3 million
Drug treatment requests
 
Principle drug in about 38% of all drug treatment requests in the European Union
Fatal overdoses
 

Opioids are found in 81% of fatal overdoses

630 000Opioid users received substitution treatment in 2015
New psychoactive substances
15- to 16-year-old school students in 24 European countries
Used:
Last year
 
Lifetime
 
NB

For the complete set of data and information on the methodology, see the accompanying online Statistical Bulletin